Search
Search
About
Log in
Join
Experiences with
Idelalisib
Posts
Communities
141 public posts
Filter results
New Treatments
Ibrutinib and
Idelalisib
have been out for a few years and help to block different areas of the b-cell receptor.
Ibrutinib and
Idelalisib
have been out for a few years and help to block different areas of the b-cell receptor.
Jemisavs5
in
CLL Support
7 years ago
Possible side effects from Ibrutinib & Idelalisib
As Ibrutinib and
Idelalisib
become more widely used among non CLL Specialists I have some concerns that side effects from both drugs may not be covered effectively by general oncologists. Both drugs are quite effective in putting the CLL Bear to sleep and both carry unique side effects.
As Ibrutinib and
Idelalisib
become more widely used among non CLL Specialists I have some concerns that side effects from both drugs may not be covered effectively by general oncologists. Both drugs are quite effective in putting the CLL Bear to sleep and both carry unique side effects.
ThreeWs
in
CLL Support
8 years ago
ASCO 2016: Dr. O'Brien on Idelalisib and liver inflammation
Susan O’Brien out of UCI where we discussed an ASCO 2016 abstract about liver inflammation associated with
idelalisib
in relapsed CLL patients.
Susan O’Brien out of UCI where we discussed an ASCO 2016 abstract about liver inflammation associated with
idelalisib
in relapsed CLL patients.
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Aggressive Follicular Lymphoma Now In NIH CAR-T Clinical Trial
Next she was in a Phase 2 Ibrutinib clinical trial that lasted 12 months followed by 14 months of
Idelalisib
/rituximab. After she progressed for the fourth time,in early 2016 she was accepted into an NIH CAR-T trial and was infused on March 2 (her new birthday). She is now in complete remission.
Next she was in a Phase 2 Ibrutinib clinical trial that lasted 12 months followed by 14 months of
Idelalisib
/rituximab. After she progressed for the fourth time,in early 2016 she was accepted into an NIH CAR-T trial and was infused on March 2 (her new birthday). She is now in complete remission.
wmay13241
in
Non Hodgkin's Lymphoma Friends
8 years ago
Dr, Jeff Jones on venetoclax after failing ibrutinib or idelalisib
Jeff Jones from ASH 2015 where we discussed the use of venetoclax for those who relapse after ibrutinib and
idelalisib
.
Jeff Jones from ASH 2015 where we discussed the use of venetoclax for those who relapse after ibrutinib and
idelalisib
.
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
Adding additional chemo
If there is still no change in November, my Oncologist will add either .bendamustine and rituximab via infusion or an additional oral med called
idelalisib
. I am told the
idelalisib
carries many side effects.... Thoughts anyone?
If there is still no change in November, my Oncologist will add either .bendamustine and rituximab via infusion or an additional oral med called
idelalisib
. I am told the
idelalisib
carries many side effects.... Thoughts anyone?
lyn26041
in
CLL Support
8 years ago
Idelalisib & 17p deletion
Is anybody else on my "whacky" journey with this most difficult prognosis.. It'd be good to share experiences and thoughts... Positivity all the way!
Is anybody else on my "whacky" journey with this most difficult prognosis.. It'd be good to share experiences and thoughts... Positivity all the way!
spud2212
in
CLL Support
8 years ago
Idelalisib & 17p deletion
I was diagnosed 18months ago at the age of 50 with CLL plus 17p deletion and have been on
Idelalisib
since last October (CALIBRE trial) I have tolerated the
Idelalisib
very well and have seen all my symptoms vanish leaving me feeling 100% healthy and my blood counts next to normal.
I was diagnosed 18months ago at the age of 50 with CLL plus 17p deletion and have been on
Idelalisib
since last October (CALIBRE trial) I have tolerated the
Idelalisib
very well and have seen all my symptoms vanish leaving me feeling 100% healthy and my blood counts next to normal.
spud2212
in
CLL Support
8 years ago
Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL - Dr Kanti Rai
haven't heard the news, [i]'There have been “very exciting” developments over the last decade in the treatment of CLL[/i], Dr Kanti Rai (of CLL Rai staging fame)[i] told HemOnc Today'[/i]: http://www.healio.com/hematology-oncology/leukemia/news/online/%7Be0869ed8-e8ff-477c-b15c-176d605648c5%7D/ibrutinib-
idelalisib
-venetoclax-provide-very-exciting-developments-in-cll
haven't heard the news, [i]'There have been “very exciting” developments over the last decade in the treatment of CLL[/i], Dr Kanti Rai (of CLL Rai staging fame)[i] told HemOnc Today'[/i]: http://www.healio.com/hematology-oncology/leukemia/news/online/%7Be0869ed8-e8ff-477c-b15c-176d605648c5%7D/ibrutinib-
idelalisib
-venetoclax-provide-very-exciting-developments-in-cll
AussieNeil
Administrator
in
CLL Support
8 years ago
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Key Points
Idelalisib
as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease. Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.
Key Points
Idelalisib
as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease. Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.
Cllcanada
Top Poster CURE Hero
in
CLL Support
8 years ago
Dr Susan O'Brien Sheds Light on Role of Next-Generation Agents in CLL
[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica)
idelalisib
(Zydelig) duvelisib in trial versus ofatumumab (Arzerra) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica)
idelalisib
(Zydelig) duvelisib in trial versus ofatumumab (Arzerra) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
AussieNeil
Administrator
in
CLL Support
8 years ago
Dr. Mato on what really happens when we must stop our ibrutinib or idelalisib
He, along with 9 other institutions gathered data about their patients who discontinued either ibrutinib or
idelalisib
. You can read about the study and watch my interview with Dr.
He, along with 9 other institutions gathered data about their patients who discontinued either ibrutinib or
idelalisib
. You can read about the study and watch my interview with Dr.
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
Update
He has been on
Idelalisib
for 9 months now and his bloods are back to normal, we are so pleased with his progress and look forward to many more good times ahead.
He has been on
Idelalisib
for 9 months now and his bloods are back to normal, we are so pleased with his progress and look forward to many more good times ahead.
june65
in
CLL Support
8 years ago
CC-122
While much of the recent excitement, for very good reasons, has been about the new class of drugs that block the B-cell receptor such as ibrutinib and
idelalisib
, or the fresh approval of venetoclax that inhibits BCL-2 leading to programmed cell death, there is still a need for more and Celgene has led
While much of the recent excitement, for very good reasons, has been about the new class of drugs that block the B-cell receptor such as ibrutinib and
idelalisib
, or the fresh approval of venetoclax that inhibits BCL-2 leading to programmed cell death, there is still a need for more and Celgene has led
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
Our 1st birthday, our newsletter, and a survey on how we make treatment decision.
Mato on research with pretty good news for those who relapse after ibrutinib or
idelalisib
. And much more. Plus we have a short survey https://asktellq12016.questionpro.com on how we patients and caregivers make decisions about our therapy.
Mato on research with pretty good news for those who relapse after ibrutinib or
idelalisib
. And much more. Plus we have a short survey https://asktellq12016.questionpro.com on how we patients and caregivers make decisions about our therapy.
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
Did You Hear? 6 Idelalisib Combination Trials Have Been Halted!
After serious adverse events were reported in patients, Gilead Sciences, Inc. has halted six clinical trials using
idelalisib
(Zydelig) in combination with other drugs.
After serious adverse events were reported in patients, Gilead Sciences, Inc. has halted six clinical trials using
idelalisib
(Zydelig) in combination with other drugs.
tclementi
in
CLL America Support
8 years ago
Dr. Pagel on the Risks of Frontline Idelalisib and some upcoming meetings and support groups
[http://cllsociety.org/2016/03/ash-2015-dr-john-pagel-on-
idelalisib
-as-frontline-therapy-in-cll-chronic-lymphocytic-leukemia/] In our What’s New section, we also have information of the
idelalisib
trial withdrawal which was more about deaths and infections than the liver issues that Dr.
[http://cllsociety.org/2016/03/ash-2015-dr-john-pagel-on-
idelalisib
-as-frontline-therapy-in-cll-chronic-lymphocytic-leukemia/] In our What’s New section, we also have information of the
idelalisib
trial withdrawal which was more about deaths and infections than the liver issues that Dr.
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
Follicular Lymphoma Patients and Caregivers Survey
Lymphoma Canada is preparing a submission to the panCanadian Oncology Drug Review (pCODR) for:
Idelalisib
(Zydelig) for the treatment of patients with follicular lymphoma who have received at least two prior systemic regimens and are refractory to both rituximab and an alkylating agent.
Lymphoma Canada is preparing a submission to the panCanadian Oncology Drug Review (pCODR) for:
Idelalisib
(Zydelig) for the treatment of patients with follicular lymphoma who have received at least two prior systemic regimens and are refractory to both rituximab and an alkylating agent.
LCAdmin
Lymphoma Canada
in
Lymphoma Canada
8 years ago
Idelalisib Trial frozen!
Was starting a trial on Monday with
Idelalisib
. Today I've been told the trial has been frozen. Have to discuss with the team at Birmingham next week. MRI and CT scans, and Bone marrow tests all done in the last couple of weeks. Naffed off To say the least!
Was starting a trial on Monday with
Idelalisib
. Today I've been told the trial has been frozen. Have to discuss with the team at Birmingham next week. MRI and CT scans, and Bone marrow tests all done in the last couple of weeks. Naffed off To say the least!
Aklambert
in
CLL Support
8 years ago
ASH 2015: Dr. John M Pagel on the Problems with Idelalisib as Frontline Therapy in CLL
It has been a while since I posted an interview on my blog first instead of the CLL Society website, but I thought the contrast of the broad approval of ibrutinib frontline versus the unexpected findings of significant auto-immune toxicities especially in the liver with
idelalisib
frontline needed to
It has been a while since I posted an interview on my blog first instead of the CLL Society website, but I thought the contrast of the broad approval of ibrutinib frontline versus the unexpected findings of significant auto-immune toxicities especially in the liver with
idelalisib
frontline needed to
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
1
2
3
4
...
8
Next page
Filter results
Clear filters
Posted in
All communities
CLL Support
131 results
Non Hodgkin's Lymphoma Friends
6 results
Advanced Prostate Cancer
1 result
View top 10 communities
Sort by
Most Relevant
Newest